In conclusion, our data shows miR‐124 as a tumour suppressor during GC progression, which also interacts with the Notch1 signalling pathway, thereby suggesting a miR‐124/Notch axis that may have potential therapeutic implications for GC. The gene discussed is NOTCH1; the disease is neoplasm.